The Caribbean Regulatory System

Vista sencilla de ítem
dc.creatorFigueras, Albert
dc.creatorWang, Huihui
dc.creatorExtavour, Rian Marie
dc.creatorMarquez, Patricio V.
dc.creatorBieliaieva, Kseniya
dc.date2023-08-15T22:17:57Z
dc.date2023-08-15T22:17:57Z
dc.date2023-08-15
dc.date.accessioned2026-07-01T00:34:42Z
dc.descriptionThis report focuses on the Caribbean Public Health Agency (CARPHA), one of the three multi-national public health agencies in the world, that commenced operations on Jan 1, 2013, with the aim of delivering the functions of five previous regional health institutions through one platform for greater synergy and cost-effectiveness and as the principal institutional expression of Caribbean Cooperation in Health. The activities of CARPHA include the provision of a subregional mechanism that supports regulatory action to ensure access to safe medicines, such as the subregional system for reporting adverse drug reactions (ADRs) and substandard and falsified products (VigiCarib), and the regional post marketing drug quality testing program under the CARPHA Medicines Quality Control and Surveillance Department. Another relevant CARPHA activity is reviewing new medicines which want to enter the Caribbean market. This was especially important during the COVID-19 pandemic, with the plethora of new vaccines. VigiCarib is a good example of a subregional approach to facilitate well-functioning post marketing monitoring activities, including PV. Although this is a relatively new program, it is well established, integrates lessons from more experienced regulatory authorities, and supports small economies without specific PV programs, thus helping ensure the safety, quality, and effectiveness of medicines and vaccines. VigiCarib can serve as a model in other parts of the world where a regional approach to strengthening regulatory systems is under consideration. However, a key lesson of the experience of CARICOM, is that regional initiatives are complex and require clear objectives, harmonization, respect for the individual countries and territories, and mutual trust.
dc.description1
dc.formatapplication/pdf
dc.formattext/plain
dc.identifierhttp://documents.worldbank.org/curated/en/099740408102323424/IDU039625edf0d538048c2085760978cbdb20155
dc.identifierhttps://openknowledge.worldbank.org/handle/10986/40207
dc.identifier10.1596/40207
dc.identifier.urihttp://hdl.handle.net/123456789/406531
dc.languageEnglish
dc.languageen
dc.publisherWorld Bank, Washington, DC
dc.relationPharmacovigilance and Essential Public Health Services Series
dc.rightsCC BY-NC 3.0 IGO
dc.rightshttps://creativecommons.org/licenses/by-nc/3.0/igo
dc.rightsWorld Bank
dc.subjectPUBLIC HEALTH COOPERATION
dc.subjectREGULATORY MEDICINE REVIEW PROCESS
dc.subjectPHARMACOVIGILANCE
dc.subjectPUBLIC HEALTH AGENCY ADMINISTRATION
dc.subjectPHARMACEUTICAL SURVEILLANCE
dc.subjectDRUG SAFETY
dc.titleThe Caribbean Regulatory System
dc.titleA Subregional Approach for Efficient Medicine Registration and Vigilance
dc.typeReport

Archivos

Colecciones

AgroKnow